report
synthesi
antivir
activ
new
famili
nonnucleosid
antivir
deriv
indol
nucleu
modif
templat
mannich
friedelcraft
reaction
coupl
nucleophil
displac
reduct
amin
led
final
deriv
pharmacolog
test
tryptamin
deriv
found
select
inhibitori
activ
human
varicella
zoster
viru
vzv
replic
vitro
inact
varieti
dna
rna
virus
structureact
relationship
sar
studi
show
presenc
biphenyl
ethyl
moieti
acetyl
amino
group
tryptamin
prerequisit
antivzv
activ
novel
compound
show
activ
thymidin
kinas
tk
compet
tk
tkdefici
tk
vzv
strain
point
novel
mechan
antivir
action
varicella
zoster
viru
vzv
ubiquit
highli
infecti
human
viru
belong
herpesvirida
famili
classifi
within
group
aherpesvirus
also
includ
herp
simplex
viru
hsv
vzv
primari
infect
lead
acut
varicella
chickenpox
reactiv
latent
viru
establish
cranial
nerv
dorsal
root
ganglia
caus
herp
zoster
shingl
cours
varicella
gener
benign
immunecompet
children
caus
sever
morbid
mortal
adult
immunecompromis
individu
complic
herp
zoster
immunecompet
host
includ
postherpet
neuralgia
phn
persist
pain
syndrom
challeng
complic
particularli
older
individu
central
nervou
system
cn
complic
follow
primari
infect
reactiv
vzv
seriou
manifest
aris
vzv
invad
spinal
cord
cerebr
arteri
reactiv
viru
caus
diseas
myeliti
focal
vasculopathi
neurolog
complic
herp
zoster
includ
motor
neuropathi
particularli
patient
zoster
ophthalmicu
patient
acquir
immun
defici
syndrom
aid
transplant
recipi
cancer
patient
vzv
infect
associ
sever
acut
retin
necrosi
arn
diseas
poor
prognosi
outcom
varicella
herp
zoster
dramat
improv
develop
safe
effect
antivir
drug
potent
activ
vzv
three
oral
guaninebas
antivir
approv
worldwid
treatment
vzvassoci
diseas
acyclovir
valacyclovir
famciclovir
thymidin
analog
brivudin
licens
therapi
herp
zoster
european
central
american
countri
drug
nucleosid
analog
predomin
phosphoryl
virusencod
thymidin
kinas
tk
act
competit
inhibitor
viral
dna
polymeras
altern
substrat
natur
triphosph
inhibit
dna
replic
antivzv
nucleosid
inhibitor
stearylvalyl
diester
valomaciclovir
valylest
prodrug
bicycl
nucleosid
analog
bcna
clinic
investig
one
limit
use
nucleosid
deriv
emerg
singl
multipl
drug
resist
could
partial
avoid
use
non
nucleosid
compound
drug
choic
treatment
acyclovirresist
vzv
diseas
foscarnet
direct
inhibitor
viral
dna
polymeras
depend
viral
tk
activ
number
small
molecul
identifi
report
potent
select
vzv
inhibitor
differ
mechan
action
exampl
pyridin
deriv
inhibitor
viral
dna
polymeras
oxadiazolephenyl
deriv
helicaseprimas
inhibitor
namethylbenzyln
arylthiourea
deriv
interfer
function
viral
protein
impair
morphogenesi
capsid
final
seri
deriv
also
report
nonselect
vzv
inhibitor
unknown
mechan
action
given
difficulti
identifi
initi
hit
compound
field
synthes
compound
primi
subject
cellular
screen
consid
interest
use
privileg
scaffold
effect
start
point
search
antivzv
ligand
indol
bioisoster
privileg
scaffold
repres
one
import
structur
motif
drug
discoveri
wide
use
antivir
research
arbidol
delavirdin
exampl
market
indolecontain
antivir
drug
wherea
panobinostat
hdac
histon
deacetylas
inhibitor
activ
undergo
clinic
evalu
human
immunodefici
viru
hiv
type
see
fig
howev
use
indolebas
structur
research
antiherp
viru
agent
rather
unusu
henc
explor
minimum
structur
requir
antivzv
activ
start
easili
derivatiz
scaffold
two
small
librari
synthes
base
substitut
indol
b
tryptamin
c
cytotox
antivir
activ
evalu
use
cellular
assay
interest
structureact
relationship
evidenc
regard
substitu
compound
prepar
start
indol
accord
scheme
alkyl
propyl
iodid
iodid
dcmdmf
use
nah
base
gave
correspond
intermedi
respect
deriv
obtain
friedelcraft
acyl
use
chlorid
acetonitril
yield
function
mannich
reaction
use
formaldehyd
piperidineor
biphenyl
ethyl
amin
tfa
catalyst
led
deriv
yield
indol
deriv
synthes
use
start
materi
follow
twosynthet
strategi
indic
scheme
first
nalkyl
subject
mannich
reaction
obtain
correspond
aldehyd
describ
treatment
intermedi
anilin
sodium
triacetoxyborohydrid
reduct
amin
condit
led
final
product
yield
respect
hand
reaction
benzoic
acid
use
hobthbtu
coupl
agent
gave
n
benzamid
yield
nalkyl
npropyl
iodid
follow
mannich
reaction
formaldehyd
piperidin
afford
final
compound
tryptaminebas
deriv
prepar
follow
scheme
nalkyl
methyl
iodid
iodid
led
deriv
yield
respect
nucleophil
displac
bromin
atom
intermedi
differ
commerci
avail
amin
perform
microwav
condit
use
palladium
acet
catalyst
obtain
compound
yield
treatment
compound
acetyl
chlorid
gave
correspond
acetyl
deriv
yield
analog
treatment
differ
aromat
aliphat
acyl
chlorid
gave
correspond
acyl
compound
yield
carbamoyl
deriv
obtain
yield
reaction
ditertbutyl
dicarbon
dcmtea
see
scheme
acyl
deriv
except
obtain
mixtur
rotam
due
atropisomer
amid
function
confirm
roesi
experi
show
exchang
crosspeak
hydrogen
signal
two
conform
exampl
see
nmr
spectra
compound
support
inform
first
compound
evalu
abil
inhibit
replic
vzv
human
embryon
lung
hel
cell
result
compar
obtain
refer
compound
acyclovir
brivudin
tabl
antivir
activ
express
compound
concentr
requir
reduc
virusplaqu
format
vzv
shown
tabl
methyl
deriv
display
antivir
cytotox
activ
mm
substitut
piperidin
valu
mm
respect
compound
ac
derivat
indol
posit
prove
less
cytotox
z
mm
also
ineffect
inhibitor
vzvinduc
plaqu
format
similar
concentr
interest
result
obtain
tryptamin
deriv
seri
presenc
methyl
group
nindol
posit
lead
weaker
cytotox
deriv
versu
versu
mm
acyl
amin
group
also
reduc
cytotox
mm
inhibitori
effect
antivzv
activ
tryptamin
deriv
inde
abl
inhibit
replic
tkvzv
strain
valu
rang
mm
tabl
potenc
oka
strain
mm
found
compar
refer
drug
acyclovir
mm
two
order
magnitud
lower
brivudin
mm
howev
activ
compound
thymidin
kinasedefici
vzv
strain
ysr
maintain
micromolar
rang
mm
least
one
order
magnitud
activ
acyclovir
mm
brivudin
mm
activ
compound
member
herpesvirida
famili
test
hel
cell
cultur
shown
tabl
none
compound
found
activ
either
toward
cytomegaloviru
hcmv
strain
davi
strain
herp
simplex
ko
thymidin
kinasedefici
acyclovirresist
acvr
strain
herp
simplex
g
strain
compound
activ
dna
virus
vaccinia
viru
felin
herpesviru
compound
also
lack
inhibitori
activ
broad
varieti
rna
virus
includ
felin
coronaviru
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
influenza
viru
subtyp
influenza
b
viru
data
shown
explor
sar
within
tryptamin
seri
next
prepar
second
set
analog
featur
modifi
aromat
moieti
link
acetamid
group
compound
di
b
modifi
acyl
group
compound
shown
tabl
substitut
biphenyl
ethyl
moieti
rigid
naphthyl
compound
superior
analog
naphthylmethyl
group
well
introduct
biphenylmethyl
phenyloxybenzyl
moieti
led
complet
loss
antivir
activ
howev
compound
contain
methyl
group
inferior
analog
biphenylmethyl
group
less
cytotox
hand
substitut
acylmethyl
group
bulkier
alkyl
group
cyclohexyl
morpholinethyl
tertbutyloxi
group
compound
led
annihil
antivir
activ
seri
compound
benzoyl
deriv
somewhat
maintain
antivir
activ
ec
mm
display
also
reduc
cytotox
activ
mmc
mm
identif
new
famili
nonnucleosid
antivzv
agent
base
upon
indol
templat
report
shown
substitut
tryptamin
moieti
strongli
influenc
activitytox
compound
particular
concomit
presenc
biphenylethyl
methyl
phenyl
carboxi
group
amino
group
tryptamin
requisit
antivir
activ
fact
nbiphenylethyl
acetamid
deriv
display
interest
inhibit
vzv
endow
select
ratio
must
also
consid
show
similar
activ
tkvzv
strain
thu
indic
mechan
action
independ
virusencod
thymidin
kinas
addit
compound
abl
exert
antivir
activ
exclus
vzv
total
inact
member
herpesvirida
famili
well
wide
varieti
rna
viru
strain
suggest
select
action
specif
antivir
target
untarget
current
exist
compound
possibl
mechan
action
novel
class
compound
investig
reagent
start
materi
solvent
purchas
sigmaaldrich
milan
itali
use
receiv
reaction
carri
magnet
stir
roundbottom
flask
unless
otherwis
note
moisturesensit
reaction
conduct
ovendri
glasswar
posit
pressur
dri
nitrogen
use
predri
freshli
distil
solvent
microwav
assist
reaction
perform
biotag
initi
reactor
analyt
thin
layer
chromatographi
tlc
perform
precoat
glass
silica
gel
plate
mm
vwr
intern
purif
perform
flash
column
chromatographi
silica
gel
mesh
merck
millipor
nmr
spectra
record
varian
apparatu
nmr
spectra
record
spectromet
oper
mhz
respect
chemic
shift
report
spectromet
combust
microanalys
perform
carlo
erba
cnh
analyz
within
calcul
valu
confirm
puriti
final
product
gener
procedur
synthesi
nalkyl
indol
intermedi
indol
eq
eq
n
benzamid
eq
indol
eq
dissolv
mixtur
anhydr
dcmdmf
vv
magnet
stir
temperatur
set
c
solut
equival
nah
ad
portionwis
mixtur
allow
react
min
equival
alkyl
iodid
methyl
iodid
npropyl
iodid
phenyl
iodomethylbenzen
dcm
ad
dropwis
reaction
warm
room
temperatur
maintain
stir
h
reaction
quench
aqueou
solut
citric
acid
wash
brine
organ
layer
separ
dri
anhydr
filter
evapor
vacuo
crude
product
purifi
column
chromatographi
use
nhexaneethyl
acet
v
v
mobil
phase
nalkyl
compound
obtain
yield
deriv
yield
deriv
yield
deriv
yield
deriv
yield
deriv
solut
dri
ad
aluminium
trichlorid
eq
benzoyl
chlorid
eq
reaction
stir
room
temperatur
overnight
result
mixtur
dri
vacuo
reconstitut
dcm
organ
phase
wash
water
ml
dri
anhydr
filter
concentr
purifi
column
chromatographi
use
nhexaneethyl
acet
mobil
phase
compound
obtain
yield
solut
formaldehyd
eq
trifluoroacet
acid
eq
equival
proper
amin
piperidin
bifenylethilamin
ad
portionwis
solut
intermedi
eq
dcm
mixtur
stir
h
room
temperatur
wash
water
ml
dri
anhydr
filter
concentr
purifi
column
chromatographi
use
dcmmeoh
vv
mobil
phase
compound
obtain
yield
intermedi
eq
dissolv
solut
dcm
vv
room
temperatur
solut
equival
ad
mixtur
warm
reflux
h
equival
sodium
triacetoxyborohydrid
ad
portionwis
mixtur
allow
reflux
h
cool
room
temperatur
naoh
n
ad
organ
phase
separ
extract
one
time
alkalin
solut
dri
filter
concentr
vacuo
crude
product
purifi
column
chromatographi
use
mixtur
dcmmeoh
eluent
give
desir
compound
yield
respect
solut
indol
eq
dichloromethan
dmf
ml
success
ad
benzoic
acid
eq
hbtu
eq
hobt
eq
diea
eq
stir
continu
room
temperatur
h
afterward
reaction
mixtur
dilut
dichloromethan
ml
result
solut
wash
success
citric
acid
ml
ml
water
ml
dri
evapor
dryness
intermedi
obtain
flash
chromatographi
use
nhexaneethyl
acet
ratio
yield
substitut
propyl
group
indol
carri
use
condit
describ
elsewher
give
compound
yield
mannich
reaction
perform
posit
intermedi
follow
procedur
previous
describ
yield
final
compound
yield
gener
procedur
synthesi
deriv
one
equival
intermedi
dissolv
thf
eq
proper
amin
eq
tea
eq
nai
eq
ad
solut
reaction
conduct
mw
c
min
result
mixtur
filter
celit
dri
vacuo
reconstitut
dcm
organ
phase
wash
water
ml
dri
anhydr
filter
concentr
purifi
column
chromatographi
use
dcmmeoh
vv
mobil
phase
give
deriv
yield
intermedi
yield
gener
procedur
synthesi
deriv
one
equival
intermedi
dissolv
dcm
eq
proper
acyl
chlorid
eq
tea
ad
solut
reaction
conduct
min
room
temperatur
organ
phase
wash
water
ml
dri
anhydr
filter
concentr
purifi
column
chromatographi
use
nhexaneethyl
acet
vv
mobil
phase
final
deriv
obtain
atropisom
mixtur
yield
mixtur
eq
dcm
boc
eq
ad
follow
tea
eq
mixtur
allow
stir
room
temperatur
h
afterward
reaction
mixtur
dilut
dichloromethan
ml
result
solut
wash
citric
acid
ml
organ
phase
dri
evapor
dryness
compound
k
obtain
atropisom
mixtur
flash
chromatographi
use
nhexaneethyl
acet
yield
compound
evalu
differ
herp
virus
includ
varicellazost
viru
vzv
strain
oka
ys
tk
vzv
strain
ysr
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acv
r
herp
simplex
viru
type
strain
g
human
cytotox
measur
base
inhibit
hel
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
c
cell
number
determin
coulter
counter
cytostat
concentr
calcul
compound
concentr
requir
reduc
cell
growth
rel
number
cell
untreat
control
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
cytotox
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
work
support
grant
italian
ministri
educ
miur
prin
n
biolog
part
work
support
ku
leuven
goa
tba
